<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001446</url>
  </required_header>
  <id_info>
    <org_study_id>950178</org_study_id>
    <secondary_id>95-C-0178</secondary_id>
    <nct_id>NCT00001446</nct_id>
  </id_info>
  <brief_title>A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer</brief_title>
  <official_title>A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      This is a phase II study designed to evaluate the potential clinical efficacy of thalidomide&#xD;
      in patients with hormone-refractory prostate cancer.&#xD;
&#xD;
      An important aspect of this study is to characterize the pharmacokinetics of thalidomide, as&#xD;
      well as make correlations between the degree of angiogenesis occurring in a patient and the&#xD;
      activity of thalidomide.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II study designed to evaluate the potential clinical efficacy of thalidomide&#xD;
      in patients with hormone-refractory prostate cancer. Patients will be randomized to two&#xD;
      different treatment arms (low dose versus high dose). An important aspect of this study is to&#xD;
      characterize the pharmacokinetics of thalidomide, as well as make correlations between the&#xD;
      degree of angiogenesis occurring in a patient and the activity of thalidomide. Each patient&#xD;
      that has biopsiable lesions will undergo a pretreatment biopsy of their prostate (or other&#xD;
      site of soft tissue disease) and repeat after 2 to 6 months of treatment. Additional&#xD;
      information will be obtained on the changes in the circulating levels of the following growth&#xD;
      factors: bFGF, TNF, VEGF, and TGFB. Neurological complications are the primary dose-limiting&#xD;
      toxicity anticipated with chronic thalidomide administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1995</start_date>
  <completion_date>July 2001</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>64</enrollment>
  <condition>Prostatic Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
        Histologically documented adenocarcinoma of the prostate. Confirmation by the Clinical&#xD;
        Center Pathology Department required.&#xD;
&#xD;
        CT-defined soft tissue disease required for staging if prostate-specific antigen (PSA) less&#xD;
        than 20 ng/mL.&#xD;
&#xD;
        Progressive hormone-refractory disease for 1 month prior to entry (and after withdrawal of&#xD;
        any antiandrogens), documented by at least one of the following: 3 consecutive rising&#xD;
        levels of PSA at least 1 week apart. 1 measurement at least 50% greater than PSA nadir&#xD;
        after last therapy.&#xD;
&#xD;
        New bone metastasis on Tc-99 bone scintigraphy.&#xD;
&#xD;
        Progression of measurable or evaluable soft-tissue metastases.&#xD;
&#xD;
        Development of new area of disease. 25% increase in previously measured lesions.&#xD;
&#xD;
        Total androgen ablation required. Testosterone in castrate range.&#xD;
&#xD;
        Concurrent luteinizing hormone-releasing hormone (LHRH) agonist required if not surgically&#xD;
        castrated.&#xD;
&#xD;
        No prior prostate irradiation or radical prostatectomy unless other biopsiable lesions&#xD;
        available.&#xD;
&#xD;
        Urgent local problems corrected prior to entry (e.g., severe bone pain, spinal cord&#xD;
        compression, urinary flow obstruction).&#xD;
&#xD;
        No brain metastases.&#xD;
&#xD;
        PRIOR/CONCURRENT THERAPY:&#xD;
&#xD;
        Thyroid replaced concurrent to start of study for patients with chemical hypothyroidism.&#xD;
&#xD;
        Thyroid replaced prior to study for patients with clinical hypothyroidism.&#xD;
&#xD;
        Biologic Therapy: At least 4 weeks since Biologic Therapy and recovered from all toxic&#xD;
        effects.&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
        No prior suramin.&#xD;
&#xD;
        At least 4 weeks since chemotherapy and recovered from all toxic effects.&#xD;
&#xD;
        Endocrine Therapy:&#xD;
&#xD;
        See Disease Characteristics.&#xD;
&#xD;
        At least 4 weeks since hormonal therapy except LHRH agonist therapy.&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
        See Disease Characteristics.&#xD;
&#xD;
        At least 4 weeks since radiotherapy (6 weeks since strontium).&#xD;
&#xD;
        Surgery: See Disease Characteristics.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age: 18 and over.&#xD;
&#xD;
        Performance status: ECOG 0-2.&#xD;
&#xD;
        Life expectancy: More than 3 months.&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
        Absolute granulocyte count greater than 1,000/mm(3).&#xD;
&#xD;
        Platelet count greater than 75,000/mm(3).&#xD;
&#xD;
        Hemoglobin greater than 8.0 g/dL (transfusion allowed if requirement maintained for more&#xD;
        than 30 days OR bleeding identified and treated).&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
        Bilirubin no greater than 1.5 times normal.&#xD;
&#xD;
        AST and ALT less than 2.5 times normal.&#xD;
&#xD;
        Renal:&#xD;
&#xD;
        Creatinine no greater than 1.5 mg/dL OR&#xD;
&#xD;
        Creatinine clearance greater than 40 mL/min.&#xD;
&#xD;
        Proteinuria no greater than 2+ OR less than 500 mg/24 hr (except patients with ureteral&#xD;
        stents).&#xD;
&#xD;
        BUN normal.&#xD;
&#xD;
        Electrolytes normal.&#xD;
&#xD;
        Urinalysis normal.&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
        No unstable or newly diagnosed angina.&#xD;
&#xD;
        No myocardial infarction within 6 months.&#xD;
&#xD;
        No NYHA class II-IV congestive heart failure.&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
        No chronic obstructive lung disease requiring oxygen therapy.&#xD;
&#xD;
        Neurologic:&#xD;
&#xD;
        No clinically detectable peripheral neuropathy greater than grade 1.&#xD;
&#xD;
        No seizures within 10 years.&#xD;
&#xD;
        No anticonvulsants.&#xD;
&#xD;
        No requirement for sedatives or hypnotics.&#xD;
&#xD;
        OTHER:&#xD;
&#xD;
        Normal thyroid function tests at least 4 weeks prior to study and throughout study.&#xD;
&#xD;
        No concurrent anticoagulants.&#xD;
&#xD;
        No active infection.&#xD;
&#xD;
        Off antibiotics at least 1 week.&#xD;
&#xD;
        Ureteral stent or Foley catheter allowed with no antibiotics.&#xD;
&#xD;
        HIV negative.&#xD;
&#xD;
        No concurrent life-threatening illness.&#xD;
&#xD;
        No concurrent malignancies.&#xD;
&#xD;
        Ability to travel to the National Institutes of Health.&#xD;
&#xD;
        Adequate contraception required of sexually active patients and their partners during and&#xD;
        for 2 months after therapy.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Cancer Institute (NCI)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bakay B, Nyhan WL. Binding of thalidomide by macromolecules in the fetal and maternal rat. J Pharmacol Exp Ther. 1968 Jun;161(2):348-60. No abstract available.</citation>
    <PMID>5652850</PMID>
  </reference>
  <reference>
    <citation>Barnhill RL, McDougall AC. Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions. J Am Acad Dermatol. 1982 Sep;7(3):317-23. doi: 10.1016/s0190-9622(82)70118-5.</citation>
    <PMID>7130490</PMID>
  </reference>
  <verification_date>August 2000</verification_date>
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>December 9, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2002</study_first_posted>
  <last_update_submitted>March 3, 2008</last_update_submitted>
  <last_update_submitted_qc>March 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2008</last_update_posted>
  <keyword>Angiogenesis</keyword>
  <keyword>Malignancy</keyword>
  <keyword>Neuropathy</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Sedation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

